Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration: One-Year Findings from the IVAN Randomized Trial.

Purpose
To compare the efficacy and safety of ranibizumab and bevacizumab intravitreal injections to treat neovascular age-related macular degeneration (nAMD).

Design
Multicenter, noninferiority factorial trial with equal allocation to groups. The noninferiority limit was 3.5 letters. This trial is registered (ISRCTN92166560).

Participants
People >50 years of age with untreated nAMD in the study eye who read =25 letters on the Early Treatment Diabetic Retinopathy Study chart.

Methods
We randomized participants to 4 groups: ranibizumab or bevacizumab, given either every month (continuous) or as needed (discontinuous), with monthly review.

Main Outcome Measures
The primary outcome is at 2 years; this paper reports a prespecified interim analysis at 1 year. The primary efficacy and safety outcome measures are distance visual acuity and arteriothrombotic events or heart failure. Other outcome measures are health-related quality of life, contrast sensitivity, near visual acuity, reading index, lesion morphology, serum vascular endothelial growth factor (VEGF) levels, and costs.

Results
Between March 27, 2008 and October 15, 2010, we randomized and treated 610 participants. One year after randomization, the comparison between bevacizumab and ranibizumab was inconclusive (bevacizumab minus ranibizumab -1.99 letters, 95% confidence interval [CI], -4.04 to 0.06). Discontinuous treatment was equivalent to continuous treatment (discontinuous minus continuous -0.35 letters; 95% CI, -2.40 to 1.70). Foveal total thickness did not differ by drug, but was 9% less with continuous treatment (geometric mean ratio [GMR], 0.91; 95% CI, 0.86 to 0.97; P = 0.005). Fewer participants receiving bevacizumab had an arteriothrombotic event or heart failure (odds ratio [OR], 0.23; 95% CI, 0.05 to 1.07; P = 0.03). There was no difference between drugs in the proportion experiencing a serious systemic adverse event (OR, 1.35; 95% CI, 0.80 to 2.27; P = 0.25). Serum VEGF was lower with bevacizumab (GMR, 0.47; 95% CI, 0.41 to 0.54; P<0.0001) and higher with discontinuous treatment (GMR, 1.23; 95% CI, 1.07 to 1.42; P = 0.004). Continuous and discontinuous treatment costs were £9656 and £6398 per patient per year for ranibizumab and £1654 and £1509 for bevacizumab; bevacizumab was less costly for both treatment regimens (P<0.0001).

Conclusions
The comparison of visual acuity at 1 year between bevacizumab and ranibizumab was inconclusive. Visual acuities with continuous and discontinuous treatment were equivalent. Other outcomes are consistent with the drugs and treatment regimens having similar efficacy and safety.

Financial Disclosure(s)
Proprietary or commercial disclosures may be found after the references.

Poverty and power: the Irish Poor Law in a north Antrim town 1861-1921

This examines the workings of the Irish Poor Law in the town of Ballymoney, Co. Antrim, during the period between the end of the Great Famine and Partition. It focuses both on those who administered and those who used the poor law and argues that for the former it provided an important route into local politics and for the latter it represented a crucial strand in the limited strategies for survival open to them. It also demonstrates the impact that local political outlook had on both the administration and the experience of poor relief.

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

Background: Bevacizumab has been suggested to have similar effectiveness to ranibizumab for treatment of neovascular age-related macular degeneration. The Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) trial was designed to compare these drugs and different regimens. Here, we report the findings at the prespecified 2-year timepoint. Methods: In a multicentre, 2×2 factorial, non-inferiority randomised trial, we enrolled adults aged at least 50 years with active, previously untreated neovascular age-related macular degeneration and a best corrected distance visual acuity (BCVA) of at least 25 letters from 23 hospitals in the UK. Participants were randomly assigned (1:1:1:1) to intravitreal injections of ranibizumab (0·5 mg) or bevacizumab (1·25 mg) in continuous (every month) or discontinuous (as needed) regimens, with monthly review. Study participants and clinical assessors were masked to drug allocation. Allocation to continuous or discontinuous treatment was masked up to 3 months, at which point investigators and participants were unmasked. The primary outcome was BCVA at 2 years, with a prespecified non-inferiority limit of 3·5 letters. The primary safety outcome was arterial thrombotic event or hospital admission for heart failure. Analyses were by modified intention to treat. This trial is registered, number ISRCTN92166560. Findings: Between March 27, 2008, and Oct 15, 2010, 628 patients underwent randomisation. 18 were withdrawn; 610 received study drugs (314 ranibizumab; 296 bevacizumab) and were included in analyses. 525 participants reached the visit at 2 years: 134 ranibizumab in continuous regimen, 137 ranibizumab in discontinuous regimen, 127 bevacizumab in continuous regimen, and 127 bevacizumab in discontinuous regimen. For BCVA, bevacizumab was neither non-inferior nor inferior to ranibizumab (mean difference -1·37 letters, 95% CI -3·75 to 1·01; p=0·26). Discontinuous treatment was neither non-inferior nor inferior to continuous treatment (-1·63 letters, -4·01 to 0·75; p=0·18). Frequency of arterial thrombotic events or hospital admission for heart failure did not differ between groups given ranibizumab (20 [6%] of 314 participants) and bevacizumab (12 [4%] of 296; odds ratio [OR] 1·69, 95% CI 0·80-3·57; p=0·16), or those given continuous (12 [4%] of 308) and discontinuous treatment (20 [7%] of 302; 0·56, 0·27-1·19; p=0·13). Mortality was lower with continuous than discontinuous treatment (OR 0·47, 95% CI 0·22-1·03; p=0·05), but did not differ by drug group (0·96, 0·46-2·02; p=0·91). Interpretation: Ranibizumab and bevacizumab have similar efficacy. Reduction in the frequency of retreatment resulted in a small loss of efficacy irrespective of drug. Safety was worse when treatment was administered discontinuously. These findings highlight that the choice of anti-VEGF treatment strategy is less straightforward than previously thought.

Letter, to Oliver Hawes Spencer, Cheraw, SC, 1824 March 25

This letter is from Henry D. to O. H. Spencer.

[21 lettres autographes signées de Léon Halévy à Jacques Léopold Heugel, 1861?-1875]

1er juillet [1861] : Promet un article sur la distribution des récompenses des Salons et des Concours où il rappellera le nom et les oeuvres de Gustave Doré dont il a "le talent en grande estime" : "Le concours de sculpture a été très fort ; le nombre de médailles est trop restreint, et les Grands Prix de Rome toujours favorisés". Evoque aussi le nom de Charles Garnier : "Le "Sujet d'Opéra" de Garnier a obtenu la première médaille d'architecture. Décision tout exceptionnelle et très flatteuse car l'oeuvre ne faisait point partie, à proprement parler, de l'Exposition d'Architecture" (NLAS-212-1). - Février 1865 : Réclame un droit de réponse à un article de Blaze de Bury paru dans le "Ménestrel". La lettre contient également la réponse de Heugel datée du 3 février 1865 dans laquelle l'éditeur lui demande d'adoucir ses propos (NLAS-212-9). - 30 juillet 1866 : Echanges et négociations au sujet de la publication de "Tobie" de Fromental Halévy. Est vexé que l'éditeur ne voie pas dans cette parution une bonne affaire et rappelle qu'il a donné au "Ménestrel" "à titre purement gratuit" un travail important sur l'oeuvre de son frère, alors que tant d'autres collègues sont très bien payés pour fournir des notices sur des compositeurs auxquelles il reproche "un esprit de dénigrement à l'égard de [s]on cher frère". Tente de rendre justice à son frère : "Je ne puis cependant m'empêcher de remarquer, quand j'entre chez vous, qu'à côté des bustes ou portraits de Meyerbeer, de Rossini, d'Auber, qui décorent vos magasins, je ne vois pas une seule image du grand maître qui fut leur égal" (NLAS-212-11). - 2 août 1866 : Le remercie pour le témoignage personnel de ses sentiments à l'égard de son "cher et regretté frère" : "cette justice que vous lui avez toujours rendue me dédommage amplement des torts que peuvent avoir envers sa mémoire plusieurs écrivains qui ont coopéré avec moi au monument que vous élevez à la gloire de nos grands maîtres français et étrangers" (NLAS-212-12). - 25 avril 1867 : au sujet des droits d'auteur de "Tobie" (NLAS-212-16). - 7 mai 1873 : Se dit heureux que son article convienne au directeur du "Ménestrel". Évoque "Carmen" de Bizet : "Ludovic [Halévy] et Meilhac sont à l'oeuvre et achèvent un poème où l'ami Bizet aura toute occasion de déployer son talent" (NLAS-212-17). - 16 juin 1875 : Le remercie pour son article consacré à "[leur] cher et infortuné Bizet" : "Impossible de rendre un hommage plus complet et en meilleurs termes à une existence si courte et si bien remplie" (NLAS-212-19). - 22 juin 1875 : Au sujet d'un opéra inachevé de Bizet, "Le Cid" : "La seule personne qui pourrait vous donner des renseignements que vous désirez sur l'opéra laissé inachevé par Bizet [...] serait sa jeune et malheureuse veuve, ma pauvre nièce Geneviève, mais elle est dans un tel état de prostration, d'accablement et d'inconsolable affliction qu'il est encore impossible de l'interroger sur un sujet si douloureux pour elle et qui raviverait de si poignants souvenirs" (NLAS-212-20). - Contient aussi 2 LAS de sa belle-soeur Léonie Halévy au sujet de sa fondation "Le Pain à bon marché" (NLAS-212-22/23)

[Voyage en Italie : 1824-1830]. , Portique d'Octavie à Rome. Détails de la Couverture en Marbre au huitième de l'Ex[écu]tion : [huit motifs] : [dessin] / h. L. [Henri Labrouste]

Référence bibliographique : Weigert, 589